Stoke Therapeutics, Inc

Newest shelf

No limit

S-3ASR of 2026-03-18. An automatic shelf: the form sets no dollar limit. 1 prospectus supplement filed under it since. S-3ASR ↗

At the market

$200.0M

Cantor Fitzgerald, agreement of 2026-08-03. No at-the-market sales statement read from a 10-Q or 10-K. 424B5 ↗

Warrants

The 10-Q filed 2026-08-03 is not read yet.

Cash

6.6 quarters

$292.8M on 2026-06-30 ÷ $44.5M a quarter of operating cash used, the average of four quarters. 10-Q ↗